Department of Pharmaceutical Chemistry and Drug Analysis, Vrije Universiteit Brussel, Brussels, Belgium.
Neurochem Int. 2010 Nov;57(5):572-8. doi: 10.1016/j.neuint.2010.07.004. Epub 2010 Jul 17.
Striatal dopamine loss in Parkinson's disease is accompanied by a dysregulation of corticostriatal glutamatergic neurotransmission. Within this study, we investigated striatal expression and activity of the glial high-affinity Na(+)/K(+)-dependent glutamate transporters, GLT-1 and GLAST, in the 6-hydroxydopamine hemi-Parkinson rat model at different time points after unilateral 6-hydroxydopamine injection into the medial forebrain bundle. Using semi-quantitative Western blotting and an ex vivo D-[(3)H]-aspartate uptake assay, we showed a time-dependent bilateral effect of unilateral 6-hydroxydopamine lesioning on the expression as well as activity of GLT-1. At 3 and 12 weeks post-lesion, striatal GLT-1 function was bilaterally upregulated whereas at 5 weeks there was no change. Even though our data do not allow a straightforward conclusion as for the role of glutamate transporters in the pathogenesis of the disease, they do clearly demonstrate a link between disturbed glutamatergic neurotransmission and glutamate transporter functioning in the striatum of a rat model for Parkinson's disease.
帕金森病患者纹状体多巴胺的丧失伴随着皮质纹状体谷氨酸能神经传递的失调。在这项研究中,我们在单侧 6-羟多巴胺注入内侧前脑束后不同时间点,研究了 6-羟多巴胺半帕金森大鼠模型中胶质细胞高亲和力 Na(+)/K(+)-依赖性谷氨酸转运体 GLT-1 和 GLAST 的纹状体表达和活性。通过半定量 Western 印迹和体外 D-[(3)H]-天冬氨酸摄取测定,我们显示了单侧 6-羟多巴胺损伤对 GLT-1 表达和活性的双侧时间依赖性影响。在损伤后 3 周和 12 周,纹状体 GLT-1 功能双侧上调,而在 5 周时没有变化。尽管我们的数据不允许对谷氨酸转运体在疾病发病机制中的作用做出直接的结论,但它们确实清楚地表明了帕金森病大鼠模型中谷氨酸能神经传递紊乱与纹状体谷氨酸转运体功能之间的联系。